AbbVie (ABBV) Asset Writedowns and Impairment (2018 - 2024)

AbbVie has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting $4.5 billion for Q4 2024.

• In Q4 2024, Asset Writedowns and Impairment rose 218.58% year-over-year to $4.5 billion; the TTM figure through Dec 2025 stood at $4.5 billion (changed 0.0% YoY), while the FY2025 annual figure was $847.0 million, down 81.08% from the prior year.
• Asset Writedowns and Impairment improved to $4.5 billion in Q4 2024, from $1.4 billion in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for ABBV reached as high as $4.5 billion in Q4 2024 and fell as low as $80.0 million in Q2 2023.
• The 3-year median for Asset Writedowns and Impairment is $1.1 billion (2022), against an average of $1.6 billion.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment soared 174.55% — and 2024, when it jumped 218.58%.
• A 3-year view of Asset Writedowns and Impairment shows it stood at $770.0 million in 2022, then surged by 82.47% to $1.4 billion in 2023, then jumped by 218.58% to $4.5 billion in 2024.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $4.5 billion, $1.4 billion, and $2.1 billion for Q4 2024, Q4 2023, and Q3 2023 respectively.